Similar Efficacy, Safety, and Immune Improvement Through 96 Weeks in Individuals With Limited HIV-1 Treatment Options Using Twice-Daily Dolutegravir- or Fostemsavir-based Regimens
Antonella Castagna, Iacopo Marcon, Fangfang Du, Bo Li et autres
0 citationsOpen Forum Infectious Diseases